Search results for "trials"

showing 10 items of 966 documents

The mediterranean diet and menopausal health: An EMAS position statement

2020

Introduction: Globally, 985 million women are aged 50 and over, leading to increasing concerns about chronic conditions such as cardiovascular disease, osteoporosis, dementia, and cognitive decline, which can adversely affect quality of life and independent living.Aim: To evaluate the evidence from observational studies and randomized trials on the effects of the Mediterranean diet on short- and long-term menopausal health: estrogen deficiency symptoms, cardiovascular disease, osteoporosis, cognitive and mental health, breast cancer, and all-cause mortality.Materials and methods: Literature review and consensus of expert opinion.Summary recommendations: The Mediterranean diet is a non-restr…

ConsensusMediterranean dietOsteoporosisBreast NeoplasmsDiseaseDiet MediterraneanGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineBreast cancerEnvironmental healthmedicineHumansDementia030212 general & internal medicineCognitive declineDepression (differential diagnoses)Randomized Controlled Trials as Topic030219 obstetrics & reproductive medicineMediterranean Dietbusiness.industryObstetrics and GynecologyNon-communicable diseasemedicine.diseaseObservational Studies as TopicNon-Communicable DiseaseMental HealthCardiovascular DiseasesHealthOsteoporosisWomen's HealthDementiaFemaleMenopausebusiness
researchProduct

Chloroquine for COVID-19: rationale, facts, hopes

2020

The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?

Coronavirus disease 2019 (COVID-19)Treatment outcomeCoronaviruPneumonia ViralMEDLINECritical Care and Intensive Care Medicinemedicine.disease_causeAntiviral AgentsAntimalarialsBetacoronavirusChloroquinePandemicmedicineHumansPandemicsCoronavirusClinical Trials as Topicbiologybusiness.industrySARS-CoV-2lcsh:Medical emergencies. Critical care. Intensive care. First aidCOVID-19Chloroquinelcsh:RC86-88.9Pneumoniabiology.organism_classificationmedicine.diseaseVirologyCOVID-19 Drug TreatmentCoronavirusPneumoniaTreatment OutcomeEditorialbusinessCoronavirus InfectionsCOVID-19 ; Chloroquine ; Pneumonia ; SARS-CoV-2 ; CoronavirusBetacoronavirusmedicine.drug
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Counselling for physical activity, life-space mobility and falls prevention in old age (COSMOS): protocol of a randomised controlled trial.

2019

IntroductionThe most promising way to promote active life years in old age is to promote regular participation in physical activity (PA). Maintaining lower extremity muscle function with good balance has been associated with fewer falls and the need of help from others. This article describes the design and intervention of a randomised controlled trial (RCT) investigating the effectiveness of a health and PA counselling programme on life-space mobility and falls rates in community-dwelling older adults at the Health Kiosk and/or Service Centre.Methods and analysisCommunity-dwelling men and women (n=450) aged 65 years and over with early phase mobility limitation will be recruited to a 24-mo…

CounselingMalephysical activityFear of fallinglaw.inventionolder people0302 clinical medicineRandomized controlled triallawActivities of Daily LivingPreventive Health ServicesfallsProtocolMedicine030212 general & internal medicine1506Postural BalanceRandomized Controlled Trials as TopickaatuminenSisätaudit - Internal medicineCognitionGeneral Medicine3. Good healthcounsellingFemaleIndependent LivingPublic Healthmedicine.symptomikääntyneetfyysinen aktiivisuusmedicine.medical_specialtylife-space mobilityterveyden edistäminen03 medical and health sciencesterveysneuvontaQuality of life (healthcare)Intervention (counseling)liikuntakykyHumans1724Mobility LimitationExerciseBalance (ability)AgedProtocol (science)business.industryResistance TrainingMoodPhysical therapyQuality of LifeAccidental Fallsbusiness030217 neurology & neurosurgeryProgram EvaluationBMJ open
researchProduct

Causes of and prevention strategies for hepatocellular carcinoma.

2012

Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behav…

Counselingmedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeGastroenterologyChemopreventionInternal medicineMedicineHumansRisk factorHepatitis B virusbusiness.industryIncidence (epidemiology)Hepatocellular carcinoma primary prevention chemopreventionFatty liverLiver NeoplasmsVaccinationHematologymedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesOncologyHepatocellular carcinomaControlled Clinical Trials as TopicInterferonsbusinessSeminars in oncology
researchProduct

Applying univariate vs. multivariate statistics to investigate therapeutic efficacy in (pre)clinical trials: A Monte Carlo simulation study on the ex…

2020

BackgroundSmall sample sizes combined with multiple correlated endpoints pose a major challenge in the statistical analysis of preclinical neurotrauma studies. The standard approach of applying univariate tests on individual response variables has the advantage of simplicity of interpretation, but it fails to account for the covariance/correlation in the data. In contrast, multivariate statistical techniques might more adequately capture the multi-dimensional pathophysiological pattern of neurotrauma and therefore provide increased sensitivity to detect treatment effects.ResultsWe systematically evaluated the performance of univariate ANOVA, Welch's ANOVA and linear mixed effects models ver…

Critical Care and Emergency MedicineScienceStatistics as TopicTest StatisticsGeometryResearch and Analysis Methods570 Life sciencesMathematical and Statistical TechniquesMedicine and Health SciencesHumansStatistical MethodsResearch ErrorsTrauma MedicinePrincipal Component AnalysisAnalysis of VarianceClinical Trials as TopicSimulation and ModelingStatisticsQRResearch AssessmentMonte Carlo methodEllipsesBrain InjuriesSample SizeMultivariate AnalysisPhysical SciencesMedicineTraumatic InjuryNeurotraumaMathematics570 BiowissenschaftenResearch ArticlePLoS ONE
researchProduct

« Autonomy in the Dock: Oscar Wilde’s first trial »

2014

Les procès d’Oscar Wilde de 1895 ont donné lieu à de multiples interprétations qui soulignent en particulier comment ils ont permis la cristallisation d’une identité gaie. Ils méritent également d’être mis en relation avec le texte de Wilde « The Soul of Man under Socialism » (1891) qui propose une subjectivité fondée sur l’individualisme et l’autonomie personnelle. Ce projet qui a fort inquiété les juges et l’Establishment anglais n’est pas sans rapport avec les thèses de Cornélius Castoriadis sur l’autonomie dans la Grèce antique, référence que les deux auteurs partagent. The 1895 Wilde trials are usually seen as either the trial of non-normative sexualities or as enabling a definition of…

Cultural Studies[ SHS.HIST ] Humanities and Social Sciences/History[SHS.LITT]Humanities and Social Sciences/LiteratureLiterature and Literary Theoryidentité gaymedia_common.quotation_subjectgay identityWilde (Oscar)procès 1895[SHS]Humanities and Social Sciences[SHS.LITT] Humanities and Social Sciences/LiteratureIndividualism[ SHS ] Humanities and Social Sciencessubjectivityautonomymedia_commonGreeceindividualisme1895 trialsArtCastoriadis (Cornelius)trial[ SHS.LITT ] Humanities and Social Sciences/Literature16. Peace & justiceindividualism[SHS.HIST] Humanities and Social Sciences/Historylcsh:DA1-995Ethnology[SHS] Humanities and Social Sciencesautonomielcsh:History of Great BritainGrèceWilde[SHS.HIST]Humanities and Social Sciences/HistoryHumanitiesAutonomy
researchProduct

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with…

2017

Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), …

CyclopropanesCompassionate Use TrialsLiver CirrhosisMalechemistry.chemical_compound0302 clinical medicine2-NaphthylamineHCV direct-acting antiviral mixed cryoglobulinemia RBVAnilides030212 general & internal medicineLongitudinal StudiesProspective StudiesChronicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; UracilSettore MED/12 - GastroenterologiaSulfonamidesDasabuvirHCV DAAGastroenterologyvirus diseasesValineMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CTreatment OutcomeGastroenterology; HepatologyCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Hepatology; GastroenterologyHepatitis C virus genotype 1 Hepatitis C virus genotype 4 decompensated liver cirrhosis antiviral therapy dasabuvir ombitasvir paritaprevirHepatology; GastroenterologyAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansDecompensationAdverse effectUracilAgedRitonavirHepatologybusiness.industryRibavirinHepatitis C ChronicVirologyOmbitasvirClinical trialchemistryParitaprevirRitonavirCarbamatesbusiness
researchProduct

Daratumumab for the Treatment of Multiple Myeloma

2018

This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

Cytotoxicity Immunologic0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyAdenosineTreatment outcomeImmunologyDrug Evaluation PreclinicalComplementAntineoplastic AgentsMyelomaimmunomodulationImmunomodulation03 medical and health sciences0302 clinical medicineAntibodies monoclonalimmune system diseasesInternal medicineDaratumumabhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansImmunology and AllergycomplementMultiple myelomaNeonatal Fc-receptorsClinical Trials as Topicbusiness.industryAntibody-Dependent Cell CytotoxicityAntibodies MonoclonalDaratumumabmedicine.diseasedaratumumabTrogocytosis3. Good healthTreatment Outcome030104 developmental biologymyelomaadenosine030220 oncology & carcinogenesisAntibody-dependent cell cytotoxicityMultiple Myelomabusinesslcsh:RC581-607CD38Frontiers in Immunology
researchProduct

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials

2019

Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be ca…

Data Analysis0301 basic medicineOncologymedicine.medical_specialtyMicroarrayconsensus molecular subtypesColorectal cancermedicine.medical_treatmentDatasets as TopicReviews03 medical and health sciencesstratification0302 clinical medicineBiasCàncer colorectalInternal medicineBiomarkers TumormedicineHumansRNA-SeqOligonucleotide Array Sequence AnalysisClinical Trials as Topicclinical trialsbusiness.industryPatient SelectionBiochemical markersbiomarkersChemoradiotherapypersonalized medicineHematologyPrognosismedicine.diseaseChemotherapy regimenPrimary tumorColorectal cancerSubtypingRadiation therapyClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationgene expressionPersonalized medicineNeoplasm Recurrence LocalColorectal NeoplasmsbusinessMarcadors biomquímics
researchProduct